ForwardHealth Update 2009-71 - Revised Prior Authorization Drug ...
ForwardHealth Update 2009-71 - Revised Prior Authorization Drug ...
ForwardHealth Update 2009-71 - Revised Prior Authorization Drug ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Update</strong><br />
October <strong>2009</strong><br />
No. <strong>2009</strong>-<strong>71</strong><br />
Affected Programs: BadgerCare Plus, Medicaid, SeniorCare<br />
To: Dentists, Federally Qualified Health Centers, Home Health Agencies, Nurses in Independent Practice, Nurse<br />
Practitioners, Nursing Homes, Pharmacies, Physician Assistants, Physician Clinics, Physicians, Podiatrists, Rural Health<br />
Clinics, HMOs and Other Managed Care Programs<br />
<strong>Revised</strong> <strong>Prior</strong> <strong>Authorization</strong> <strong>Drug</strong> Attachment for<br />
Synagis ® Form and Completion Instructions<br />
<strong>ForwardHealth</strong> has revised the <strong>Prior</strong> <strong>Authorization</strong> <strong>Drug</strong><br />
Attachment for Synagis ® , F-00142 (10/09), to correct<br />
the listed weight range table and to clarify clinical criteria<br />
for pre-term infants.<br />
<strong>ForwardHealth</strong> has revised the <strong>Prior</strong> <strong>Authorization</strong><br />
<strong>Drug</strong> Attachment for Synagis ® , F-00142 (10/09), to<br />
correct an incorrectly listed weight range table and<br />
clarify clinical criteria for pre-term infants born at or<br />
greater than 32 weeks gestation to less than 35 weeks<br />
gestation. Providers may refer to Attachments 1 and 2 of<br />
this <strong>ForwardHealth</strong> <strong>Update</strong> for the revised completion<br />
instructions and form.<br />
Corrected Weight Range Table for<br />
Synagis ®<br />
The following table lists the corrected weight range, the<br />
calculated Synagis ® dose, and the number of 50 mg units<br />
of Synagis ® . The table is used for the adjudication of<br />
prior authorization (PA) requests to determine the<br />
allowed billing units.<br />
Weight Range<br />
(in kg)<br />
Synagis ®<br />
Calculated Dose<br />
Up to 3.6 kg 0 - 54 mg 1<br />
3.7 to 6.9 kg 55 mg - 104 mg 2<br />
7.0 to 10.2 kg 105 mg - 154 mg 3<br />
10.3 to 13.6 kg 155 mg - 204 mg 4<br />
13.7 to 16.9 kg 205 mg - 254 mg 5<br />
17.0 to 20.3 kg 255 mg - 304 mg 6<br />
* Units are a 50 mg dose.<br />
<strong>Prior</strong> <strong>Authorization</strong> Amendments<br />
Number<br />
of Units *<br />
The <strong>Drug</strong> <strong>Authorization</strong> and Policy Override (DAPO)<br />
Center reviewed all approved PAs to determine whether<br />
or not the corrected weight ranges resulted in a change in<br />
the number of Synagis ® units. The DAPO Center<br />
amended approved PAs, if appropriate, and notified<br />
providers that their PAs were amended.<br />
Clarified Clinical Criteria<br />
The <strong>Prior</strong> <strong>Authorization</strong> <strong>Drug</strong> Attachment for Synagis<br />
did not specify that pre-term infants born at or greater<br />
than 32 weeks gestation to less than 35 weeks gestation<br />
includes infants that are less than 3 months of age at the<br />
start of the respiratory syncytial virus (RSV) season and<br />
infants are born during the RSV season.<br />
Department of Health Services
The Microsoft Word ® and Portable Document Format<br />
version of the <strong>Prior</strong> <strong>Authorization</strong> <strong>Drug</strong> Attachment for<br />
Synagis has been revised and is available for printing<br />
from the Forms page of the Portal. The revised version<br />
of the form will be available to complete on the Portal in<br />
the near future.<br />
Information Regarding Managed Care<br />
Organizations<br />
This <strong>Update</strong> contains fee-for-service policy and applies to<br />
services members receive on a fee-for-service basis only.<br />
For managed care policy, contact the appropriate<br />
managed care organization. Managed care organizations<br />
are required to provide at least the same benefits as those<br />
provided under fee-for-service arrangements.<br />
The <strong>ForwardHealth</strong> <strong>Update</strong> is the first source of program<br />
policy and billing information for providers.<br />
Wisconsin Medicaid, BadgerCare Plus, SeniorCare, and<br />
Wisconsin Chronic Disease Program are administered by<br />
the Division of Health Care Access and Accountability,<br />
Wisconsin Department of Health Services (DHS). The<br />
Wisconsin Well Woman Program is administered by the<br />
Division of Public Health, Wisconsin DHS.<br />
For questions, call Provider Services at (800) 947-9627<br />
or visit our Web site at www.forwardhealth.wi.gov/.<br />
P-1250<br />
<strong>ForwardHealth</strong> Provider Information October <strong>2009</strong> No. <strong>2009</strong>-<strong>71</strong> 2
ATTACHMENT 1<br />
<strong>Prior</strong> <strong>Authorization</strong> <strong>Drug</strong> Attachment for Synagis ®<br />
Completion Instructions<br />
(A copy of the “<strong>Prior</strong> <strong>Authorization</strong> <strong>Drug</strong> Attachment for Synagis ® Completion<br />
Instructions” is located on the following pages.)<br />
<strong>ForwardHealth</strong> Provider Information October <strong>2009</strong> No. <strong>2009</strong>-<strong>71</strong> 3
(This page was intentionally left blank.)<br />
<strong>ForwardHealth</strong> Provider Information October <strong>2009</strong> No. <strong>2009</strong>-<strong>71</strong> 4
DEPARTMENT OF HEALTH SERVICES STATE OF WISCONSIN<br />
Division of Health Care Access and Accountability DHS 107.10(2), 152.06(3)(h), Wis. Admin. Code<br />
F-00142A (10/09) DHS 153.06(3)(g), 154.06(3)(g), Wis. Admin. Code<br />
FORWARDHEALTH<br />
PRIOR AUTHORIZATION DRUG ATTACHMENT FOR SYNAGIS ®<br />
COMPLETION INSTRUCTIONS<br />
<strong>ForwardHealth</strong> requires certain information to enable the programs to authorize and pay for medical services provided to eligible<br />
members.<br />
Members of <strong>ForwardHealth</strong> are required to give providers full, correct, and truthful information for the submission of correct and<br />
complete claims for reimbursement. This information should include, but is not limited to, information concerning enrollment status,<br />
accurate name, address, and member identification number (DHS 104.02[4], Wis. Admin. Code).<br />
Under s. 49.45(4), Wis. Stats., personally identifiable information about program applicants and members is confidential and is used for<br />
purposes directly related to <strong>ForwardHealth</strong> administration such as determining eligibility of the applicant, processing prior authorization<br />
(PA) requests, or processing provider claims for reimbursement. Failure to supply the information requested by the form may result in<br />
denial of PA or payment for the services.<br />
<strong>Prior</strong> authorization requests for Synagis ® submitted on paper require the use of this form. If necessary, attach additional pages if more<br />
space is needed. Refer to the applicable service-specific publications for service restrictions and additional documentation<br />
requirements. Provide enough information for <strong>ForwardHealth</strong> to make a determination about the request.<br />
INSTRUCTIONS<br />
Prescribers are required to complete and sign the <strong>Prior</strong> <strong>Authorization</strong> <strong>Drug</strong> Attachment for Synagis ® form, F-00142, to request PA for<br />
Synagis ® . Prescribers are required to retain a completed copy of the form.<br />
Prescribers may submit PA requests on a PA drug attachment form in one of the following ways:<br />
1) For requests submitted through the <strong>Drug</strong> <strong>Authorization</strong> and Policy Override Center, prescribers may call (800) 947-9627.<br />
2) For requests submitted on the <strong>ForwardHealth</strong> Portal, prescribers can access www.forwardhealth.wi.gov/.<br />
3) For paper PA requests by fax, prescribers should submit a <strong>Prior</strong> <strong>Authorization</strong> Request Form (PA/RF), F-11018, and the appropriate<br />
PA <strong>Drug</strong> Attachment form to <strong>ForwardHealth</strong> at (608) 221-8616.<br />
4) For paper PA requests by mail, prescribers should submit a PA/RF and the appropriate PA drug attachment form to the following<br />
address:<br />
<strong>ForwardHealth</strong><br />
<strong>Prior</strong> <strong>Authorization</strong><br />
Ste 88<br />
6406 Bridge Rd<br />
Madison WI 53784-0088<br />
Providers should make duplicate copies of all paper documents mailed to <strong>ForwardHealth</strong>. The provision of services that are greater<br />
than or significantly different from those authorized may result in nonpayment of the billing claim(s).<br />
The following table includes the weight range, the rounded calculated Synagis ® dose, and the number of 50 mg units of Synagis ® and is<br />
used for the adjudication of PA requests to determine the allowed billing units.<br />
Weight Range (in kg) Synagis ® Calculated Dose Number of Units *<br />
Up to 3.6 kg 0 - 54 mg 1<br />
3.7 to 6.9 kg 55 mg - 104 mg 2<br />
7.0 to 10.2 kg 105 mg - 154 mg 3<br />
10.3 to 13.6 kg 155 mg - 204 mg 4<br />
13.7 to 16.9 kg 205 mg - 254 mg 5<br />
17.0 to 20.3 kg 255 mg - 304 mg 6<br />
* Units are a 50 mg dose.<br />
SECTION I — MEMBER AND PROVIDER INFORMATION<br />
Element 1 — Name — Member<br />
Enter the member’s last name, first name, and middle initial. Use Wisconsin’s Enrollment Verification System (EVS) to obtain the<br />
correct spelling of the member’s name. If the name or spelling of the name on the <strong>ForwardHealth</strong> identification card and the EVS do<br />
not match, use the spelling from the EVS.
PRIOR AUTHORIZATION DRUG ATTACHMENT FOR SYNAGIS ® COMPLETION INSTRUCTIONS Page 2 of 3<br />
F-00142A (10/09)<br />
Element 2 — Member Identification Number<br />
Enter the member ID. Do not enter any other numbers or letters. Use the <strong>ForwardHealth</strong> card or the EVS to obtain the correct<br />
member ID.<br />
Element 3 — Date of Birth — Member<br />
Enter the member’s date of birth in MM/DD/CCYY format.<br />
Element 4 — Name — Prescriber<br />
Enter the name of the medical practitioner prescribing the medication for PA.<br />
Element 5 — National Provider Identifier (NPI) — Prescriber<br />
Enter the medical practitioner’s 10-digit National Provider Identifier (NPI).<br />
Element 6 — Address — Prescriber<br />
Enter the address (street, city, state, and ZIP+4 code) of the prescriber.<br />
Element 7 — Telephone Number — Prescriber<br />
Enter the telephone number, including area code, of the prescriber.<br />
Element 8 — Name — Billing Provider<br />
Enter the name of the billing provider. Prescribers who are certified by Wisconsin Medicaid should indicate their name and NPI as the<br />
billing provider on the PA request. Prescribers who are not certified by Wisconsin Medicaid should indicate on the PA request the<br />
name and NPI of the Wisconsin Medicaid-certified billing provider (e.g., clinic) with which they are affiliated.<br />
Element 9 — NPI — Billing Provider<br />
Enter the billing provider’s NPI.<br />
SECTIONS II A, II B, II C, or II D<br />
Providers are required to complete one of either Section II A, II B, II C, or II D or Section V for a PA request to be considered for<br />
approval. Providers should indicate the reason for administration of Synagis ® . Under the appropriate condition, check the boxes that<br />
apply to the member’s medical condition. Include the last date of therapy treatment in the chronic lung disease section. For a pre-term<br />
infant, the gestational age at delivery must be included.<br />
SECTION II A — CLINICAL INFORMATION FOR CHRONIC LUNG DISEASE<br />
Element 10<br />
Indicate whether or not the member is a child younger than 24 months of age at the start of the respiratory syncytial virus (RSV)<br />
season with chronic lung disease who required bronchodilator, corticosteroid, diuretic, or supplemental oxygen therapy within six<br />
months of the start of the RSV season.<br />
SECTION II B — CLINICAL INFORMATION FOR CONGENITAL HEART DISEASE<br />
Element 11<br />
Indicate whether or not the member is a child younger than 24 months of age at the start of the RSV season who has<br />
hemodynamically significant cyanotic or acyanotic congenital heart disease and is receiving medication to control congestive heart<br />
failure, has moderate to severe pulmonary hypertension, or has cyanotic heart disease.<br />
SECTION II C — CLINICAL INFORMATION FOR IMMUNOCOMPROMISED CHILDREN<br />
Element 12<br />
Indicate whether or not the member is a child younger than 24 months of age at the start of the RSV season with a severe<br />
immunodeficiency (i.e., severe combined immunodeficiency [SCID] or advanced acquired immunodeficiency syndrome [AIDS]).<br />
SECTION II D — CLINICAL INFORMATION FOR PRE-TERM INFANTS<br />
Element 13<br />
Indicate the pre-term infant’s gestational age at delivery in weeks and days. Check the appropriate box to indicate the member’s<br />
clinical condition.
PRIOR AUTHORIZATION DRUG ATTACHMENT FOR SYNAGIS ® COMPLETION INSTRUCTIONS Page 3 of 3<br />
F-00142A (10/09)<br />
Element 14<br />
Indicate whether or not the first dose of Synagis ® was administered when the child was hospitalized. Indicate the date the first dose<br />
was administered. If the first dose of Synagis ® was administered when the child was hospitalized, indicate the date the first dose was<br />
administered in MM/DD/CCYY format.<br />
Element 15 — Current Weight — Member<br />
Enter the current weight of child in kilograms.<br />
Element 16 — Date Member Weighed<br />
Enter the date the child was weighed.<br />
Element 17 — Calculated Dosage of Synagis ®<br />
Enter the monthly dose of Synagis ® in milligrams needed based on the calculation of 15 milligrams per kilogram of body weight.<br />
SECTION IV — AUTHORIZED SIGNATURE<br />
Element 18 — Signature — Prescriber<br />
The prescriber is required to complete and sign this form.<br />
Element 19 — Date Signed — Prescriber<br />
Enter the month, day, and year the form was signed by the prescriber in MM/DD/CCYY format.<br />
SECTION V — ADDITIONAL INFORMATION<br />
Element 20<br />
Indicate any additional information in the space provided. Additional diagnostic and clinical information explaining the need for the<br />
product requested may be included here.<br />
SECTION VI — INTERNAL USE ONLY<br />
This section is for internal use only.
ATTACHMENT 2<br />
<strong>Prior</strong> <strong>Authorization</strong> <strong>Drug</strong> Attachment for Synagis ®<br />
(A copy of the “<strong>Prior</strong> <strong>Authorization</strong> <strong>Drug</strong> Attachment for Synagis ® ” is located<br />
on the following pages.)<br />
<strong>ForwardHealth</strong> Provider Information October <strong>2009</strong> No. <strong>2009</strong>-<strong>71</strong> 8
DEPARTMENT OF HEALTH SERVICES STATE OF WISCONSIN<br />
Division of Health Care Access and Accountability DHS 107.10(2), 152.06(3)(h), Wis. Admin. Code<br />
F-00142 (10/09) DHS 153.06(3)(g), 154.06(3)(g), Wis. Admin. Code<br />
FORWARDHEALTH<br />
PRIOR AUTHORIZATION DRUG ATTACHMENT FOR SYNAGIS ®<br />
Instructions: Type or print clearly. Refer to the <strong>Prior</strong> <strong>Authorization</strong> <strong>Drug</strong> Attachment for Synagis ® Completion Instructions, F-00142A,<br />
for more information.<br />
Providers may call the <strong>Drug</strong> <strong>Authorization</strong> and Policy Override Center at (800) 947-9627 with questions.<br />
SECTION I — MEMBER AND PROVIDER INFORMATION<br />
1. Name — Member (Last, First, Middle Initial)<br />
2. Member Identification Number 3. Date of Birth — Member<br />
4. Name — Prescriber 5. National Provider Identifier (NPI) — Prescriber<br />
6. Address — Prescriber (Street, City, State, ZIP+4 Code) 7. Telephone Number — Prescriber<br />
8. Name — Billing Provider 9. NPI — Billing Provider<br />
Providers are required to complete one of either Section II A, II B, II C, or II D (depending on the member’s medical condition) for a<br />
prior authorization (PA) request to be considered for approval.<br />
SECTION II A — CLINICAL INFORMATION FOR CHRONIC LUNG DISEASE<br />
10. The member is a child younger than 24 months of age at the start of the respiratory syncytial<br />
virus (RSV) season with chronic lung disease who required one of the therapies below within<br />
six months of the start of the RSV season. (Chronic lung disease is not asthma, croup,<br />
recurrent upper respiratory infections, chronic bronchitis, chronic bronchiolitis, or a history of<br />
previous RSV infections.) Yes No<br />
Check all therapies below that the member has tried within the past six months.<br />
Bronchodilator Corticosteroid Diuretic Supplemental Oxygen<br />
SECTION II B — CLINICAL INFORMATION FOR CONGENITAL HEART DISEASE<br />
11. The member is a child younger than 24 months of age at the start of the RSV season with<br />
hemodynamically significant cyanotic or acyanotic congenital heart disease and is receiving medication<br />
to control congestive heart failure, has moderate to severe pulmonary hypertension, or has<br />
cyanotic heart disease. Yes No<br />
SECTION II C — CLINICAL INFORMATION FOR IMMUNOCOMPROMISED CHILDREN<br />
12. The member is a child younger than 24 months of age at the start of the RSV season with a<br />
severe immunodeficiency (i.e., severe combined immunodeficiency [SCID] or advanced<br />
acquired immunodeficiency syndrome [AIDS]). Yes No<br />
SECTION II D — CLINICAL INFORMATION FOR PRE-TERM INFANTS<br />
13. Indicate the pre-term infant’s gestational age at delivery (in weeks and days).<br />
_______________ Weeks _______________ Days<br />
Continued
PRIOR AUTHORIZATION DRUG ATTACHMENT FOR SYNAGIS ® Page 2 of 2<br />
F-00142 (10/09)<br />
SECTION II D — CLINICAL INFORMATION FOR PRE-TERM INFANTS (Continued)<br />
Check one:<br />
The member is an infant born before 29 weeks gestation (i.e., zero days through 28 weeks, six days) who is less than 12<br />
months of age at the start of the RSV season.<br />
The member is an infant born at or greater than 29 weeks gestation to less than 32 weeks gestation (i.e., 29 weeks, zero days<br />
through 31 weeks, six days) who is less than 6 months of age at the start of the RSV season.<br />
The member is an infant born at or greater than 32 weeks gestation to less than 35 weeks gestation (i.e., 32 weeks, zero days<br />
through 34 weeks, six days) who is less than 3 months of age at the start of the RSV season or was born during the RSV<br />
season and has at least one of the following risk factors: (Check all that apply.)<br />
The infant attends daycare.<br />
The infant has siblings younger than 5 years of age.<br />
The member is an infant born before 35 weeks gestation (i.e., 34 weeks, six days) who is less than 12 months of age at the start<br />
of the RSV season with either congenital abnormalities of the airway or a neuromuscular condition that compromises handling of<br />
respiratory secretions.<br />
SECTION III — ADMINISTRATION INFORMATION<br />
14. Was the first dose of Synagis ® administered when the child was hospitalized? Yes No<br />
If yes, indicate the date of administration in the space provided. (No more than five doses will be authorized, inclusive of any<br />
hospital-administered doses.)<br />
15. Current Weight — Member (In kilograms) 16. Date Member Weighed<br />
17. Calculated Dosage of Synagis ® (15 milligrams per kilogram of body weight)<br />
SECTION IV — AUTHORIZED SIGNATURE<br />
18. SIGNATURE — Prescriber 19. Date Signed — Prescriber<br />
SECTION V — ADDITIONAL INFORMATION<br />
20. Indicate any additional information in the space provided. Additional diagnostic and clinical information explaining the need for<br />
the product requested may be included here.<br />
SECTION VI — INTERNAL USE ONLY<br />
Number of units (50 mg) per dose: __________<br />
Number of doses approved: __________<br />
Initial units (50 mg) approved: __________<br />
Dates of approval: __________ to __________